|1.||Freitag, Derrick G: 3 articles (06/2014 - 08/2002)|
|2.||Foster, Robert T: 3 articles (06/2014 - 08/2002)|
|3.||Aspeslet, Launa J: 3 articles (06/2014 - 12/2008)|
|4.||Anglade, Eddy: 3 articles (01/2009 - 10/2007)|
|5.||Ling, Spencer Y: 2 articles (06/2014 - 08/2013)|
|6.||Huizinga, Robert B: 2 articles (06/2014 - 08/2013)|
|7.||Mayo, Patrick R: 2 articles (06/2014 - 08/2013)|
|8.||Aspeslet, Launa: 2 articles (02/2011 - 08/2002)|
|9.||Larouche, Richard: 1 article (06/2014)|
|10.||Ling, S Y: 1 article (12/2013)|
12/01/2008 - "The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical development program was initiated in 2007 to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. "
12/01/2008 - "A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin."
01/01/2013 - "More recently, voclosporin has been used to treat ophthalmic conditions such as uveitis. "
01/01/2013 - "Voclosporin as a treatment for noninfectious uveitis."
07/01/2010 - "In Europe, the Marketing Approval Application (MAA) of voclosporin for the treatment of uveitis was submitted to the European Medicines Agency (EMA) in February 2010 and could be approved in March 2011."
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/2011 - "Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study."
01/01/2007 - "Isotechnika completed the phase III SPIRIT trial of ISA 247 for psoriasis in Canada. "
01/01/2011 - "To determine the effect of voclosporin (VCS) treatment on quality of life in patients with psoriasis. "
09/13/2008 - "Voclosporin (ISA247) for plaque psoriasis."
01/01/2007 - "on 25 April 2006, Isotechnika has the option to obtain an exclusive licence to develop and commercialise conjugates consisting of Cellgate's patented transporter technology, for the topical delivery of ISA 247 in patients with mild-to-moderate psoriasis. "
06/01/2014 - "Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. "
12/01/2013 - "Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. "
08/01/2013 - "Voclosporin (VCS) is a novel calcineurin (CN) inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. "
|5.||Autoimmune Diseases (Autoimmune Disease)
02/01/2011 - "E-ISA247 (voclosporin) is a cyclosporin A analogue that is in late-stage clinical development for the treatment of autoimmune diseases and the prevention of organ graft rejection. "
01/01/2011 - "Voclosporin, a novel immunomodulatory drug inhibiting the calcineurin enzyme, was developed to prevent organ graft rejection and to treat autoimmune diseases. "
|3.||Collagen Type II (Type II Collagen)
|5.||Hepatitis B Vaccines (Hepatitis B Vaccine)
|9.||Fibroblast Growth Factor 1 (FGF-1)
|10.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|1.||Homologous Transplantation (Allograft)
|4.||Transplantation (Transplant Recipients)